ºÙºÙÊÓƵ

The PRECEDE Consortium aims to increase the 5-year survival rate to 50 percent within the next 10 years.

Advances in drug design are making gains against a difficult to treat cancer.

Dr. Nina D’Abreo says people should expect one-on-one care when they seek treatment with her.

Dr. Michael Shusterman says monitoring ctDNA is one way to determine who can forgo additional treatment.

Dr. Nancy Chan shares advances in targeted therapies for breast cancer that progressed after hormone therapy.

Antibody signatures are found to predict treatment success for two leading checkpoint inhibitors.

Dr. David J. Byun says the role and optimal duration of hormone therapy continue to remain controversial.

Dr. Ruth Oratz says that while the study results are exciting, more research needs to be done.

Dr. Maya Dimitrova says tumor-infiltrating lymphocyte therapy could expand available melanoma treatments.

The combination of olaparib and bevacizumab represents a new standard of care, Dr. Eva Chalas says.